Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl–mediated drug resistance

Novel therapeutic strategies are needed to address the emerging problem of imatinib resistance. The histone deacetylase (HDAC) inhibitor suberoylanilide hydroxamic acid (SAHA) is being evaluated for imatinib-resistant chronic myelogenous leukemia (CML) and has multiple cellular effects, including th...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Carew, Jennifer S., Nawrocki, Steffan T., Kahue, Charissa N., Zhang, Hui, Yang, Chunying, Chung, Linda, Houghton, Janet A., Huang, Peng, Giles, Francis J., Cleveland, John L.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2007
Témata:
Neoplasia
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC1896119/
https://ncbi.nlm.nih.gov/pubmed/17363733
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2006-10-050260
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky